

**7 June - 13 June**

## **COMPANY SPOTLIGHT**

- **InDevR** (Boulder) announced its collaboration with scientists in the Influenza Division of the Centers for Disease Control and Prevention (CDC) in Atlanta to develop a unique influenza microarray assay. InDevR and CDC scientists are working to develop a low density microarray capable of screening influenza A viruses for genetic reassortment. The microarray will be coupled with InDevR's inexpensive compact ampliPHOX™ colorimetric detection system.
- **Allos Therapeutics, Inc.** (Westminster) announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European Hematology Association (EHA) meeting being held June 10-13, 2010 in Barcelona, Spain. Of the 29 patients who received FOLOTYN at the optimal dose, 22 were evaluable for efficacy and 23 were evaluable for safety. The response rate for patients treated at the optimal dose was 45% (10/22).
- **Spectranetics Corporation** (Colorado Springs) announced its clinical trial plans related to the treatment of in-stent restenosis (ISR) in arteries above the knee, which remains a major unsolved medical problem. There is no device currently cleared or approved by the FDA to treat ISR. The Company plans to initiate a multi-center, randomized trial in the United States comparing laser ablation followed by adjunctive balloon angioplasty with balloon angioplasty alone.
- **Cell>Point** (Centennial) announced that it will present clinical results for its cancer imaging agent, 99mTc-EC-G, used to assess the efficacy of chemotherapy at the 2010 Society of Nuclear Medicine Annual Meeting on June 7, 2010. 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine) is a SPECT (Single Photon Emission Computed Tomography) cancer imaging agent Cell>Point is developing as an alternative to FDG-PET (Fluorodeoxyglucose – Positron Emission Tomography) for diagnosing and staging patients with cancer.

## **SQUARE PEGS**

- Sunday's Denver Post featured an article about the limited availability of venture capital in Colorado and the programs targeted at bridging this gap. The article is available [here](#).
- **The Medical Career Collaborative (MC2)** program at **The Children's Hospital** provides high school students from disadvantaged socio-economic backgrounds an opportunity to gain experience and exposure in the fields of health, medicine and bioscience. This two year program includes a paid internship at Children's and help with college preparation. Over the last ten years, 200 students have enrolled in MC2 and all have graduated from high school. The program is currently seeking cosponsors from the bioscience community. Please see the attached document for more information.
- Last week, **AdvaMed** issued a release to the media on the updated **Lewin report "The State Economic Impact of the Medical Technology Industry."** The media were also provided the attached documents: a copy of the Lewin study, a fact sheet summarizing the study and a copy of our testimony to the President's Council of Advisors on Science and Technology. The PCAST testimony is intended to provide context on the current state of the industry innovation ecosystem and what policies need to be in place to ensure the country's continued leadership in medical technology. [Click here to download AdvaMed's testimony](#) (PDF). The full Lewin report can be [downloaded here](#) (PDF).

## UPCOMING EVENTS

- On Wednesday, June 16, a new report prepared by **Battelle** and commissioned by the **Council for American Medical Innovation (CAMI)** will be released at the State Capitol from 10:30am - 12:00pm. The report, titled "Gone Tomorrow? A Call to Promote Medical Innovation, Create Jobs and Find Cures in America" identifies the most effective public policy ideas in the nation for maintaining U.S. leadership in medical innovation. The report presents the consensus observations of all manner of experts on opportunities to drive regulatory reform, open the flow of capital, bridge the gap between basic research and human application, and prepare our nation's young people for great careers in medical innovation. Copies of the full report will be available. [Click here for more information or to register.](#)
- **BioMARC**, the regional training center for product translation at Colorado State University, will be holding a lunch-and-learn short course sponsored by GE Healthcare on Tuesday, June 29, on "Applying Filtration, WAVE Reactor, and Chromatography Single-Use Technologies to BioProcessing". [Click here for more info or to register.](#)

- **Denver Public Schools** announced that it will be hosting a citywide career fair for its eighth graders. The event will be held on Wednesday, October 20, 2010 at the National Western Complex off of I-70 and Brighton Blvd. The primary objective of the event is to expose the students to the vast scope of careers available to them and to help them plan for their future. The school system is seeking companies to exhibit - Please see the attached documents for more information or to register your company to take part.

**SAVE THE DATE:** Please join us for the **Roche Colorado Corporation** Peptide Symposium (RCCPS) on September 14 – 16, 2010 at the St. Julian Hotel and Spa in Boulder, CO. The program highlights include; Peptides in the Clinic; Peptide Drug Delivery; Emerging Technologies; Advances in Peptide Chemistry; and, Quality by Design in Peptides. The following link [www.rccps.org](http://www.rccps.org), and attachments will provide additional information on the conference and sponsorship opportunities. We look forward to showcasing Colorado as a leader in Peptides at this conference and hope you will be able to join us! Please see attached flyer for information on sponsorship opportunities.

Kathryn Bailey  
Director, Operations & Communications  
216 16th Street, Suite 850  
Denver, CO 80202  
(303) 592-4089  
[kbailey@cobioscience.com](mailto:kbailey@cobioscience.com)